@article{3171048,
    title = "Venous Thromboembolism in Patients Diagnosed With Lung Cancer",
    author = "Salla, E. and Dimakakos, Evangelos P. and Tsagkouli, S. and Giozos, I. and and Charpidou, A. and Kainis, E. and Syrigos, K. N.",
    journal = "International Angiology",
    year = "2016",
    volume = "67",
    number = "8",
    pages = "709-724",
    publisher = "SAGE Publications Inc.",
    issn = "0392-9590",
    doi = "10.1177/0003319715614945",
    keywords = "venous thromboembolism; lung; cancer; low-molecular-weight heparin;
anticoagulant",
    abstract = "Purpose: Considering the high prevalence of lung cancer, our purpose was
to summarize the existing literature to identify the several factors
that contribute to the increased risk of venous thromboembolism (VTE) in
patients with lung cancer and to analyze the current recommendations for
thromboprophylaxis and treatment of VTE in those patients.
Methods: We searched the Medline and EMBASE databases from February 1985
to February 2014 to identify retrospective and prospective randomized
controlled studies that investigate one or more risk factors for VTEs in
patients with lung cancer.
Results: A VTE is a major complication for patients diagnosed with lung
cancer. The risk factors for VTE events in patients with lung cancer
consist of cancer-related (histological type and stage of cancer),
treatment-related (surgery, chemotherapy, angiogenic agents, and
supportive care agents), and patient-related factors (comorbidities,
immobility, performance status, and prior thrombosis).
Low-molecular-weight heparins are recommended for long-term treatment of
cancer-associated thrombosis. Duration of anticoagulant therapy beyond 6
months should be based on individual clinical evaluation.
Thromboprophylaxis for patients with lung cancer during hospitalization
and immediate postoperative period is well established.
Conclusions: Efforts to assess thrombotic risk in patients with lung
cancer may improve therapeutic and preventive strategies in the future,
with final goal to minimize the burden and consequences of thrombotic
events in patients with lung cancer."
}